Predictors of survival in immunotherapy‐based treatments in advanced melanoma: a meta‐analysis

Author:

Li Daishi12345ORCID,Sun Yuming6,Le Jiayuan12345,Dian Yating12345,Liu Yihuang12345,Zeng Furong7,Deng Guangtong12345ORCID,Lei Shaorong6,Su Juan12345

Affiliation:

1. Central South University Changsha China

2. National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology Changsha China

3. Hunan Engineering Research Center of Skin Health and Disease Central South University Changsha China

4. Hunan Key Laboratory of Skin Cancer and Psoriasis Central South University Changsha China

5. National Clinical Research Center of Geriatric Disorders, Xiangya Hospital Central South University Changsha China

6. Department of Plastic and Cosmetic Surgery, Xiangya Hospital Central South University Changsha Hunan China

7. Department of Oncology, Xiangya Hospital Central South University Changsha Hunan China

Abstract

AbstractThe introduction of immunotherapy‐based strategies has significantly improved the prognosis for melanoma patients. Nevertheless, some patients still have dismal outcomes, emphasizing the significance of survival predictive indicators in immunotherapy‐based approaches. We systematically searched randomized controlled clinical trials investigating dual immunotherapy or chemoimmunotherapy versus placebo or mono‐immunotherapy or chemotherapy alone in advanced melanoma patients. R version 4.3.0. was employed to perform all analyses. A comprehensive analysis was conducted on a total of 13,809 patients with advanced melanoma from 19 randomized clinical trials. Immunotherapy‐based strategies (alone or in combination) could significantly lengthen the overall survival(OS) and recurrence‐free survival (RFS) compared with corresponding controls. Mono‐immunotherapy improved RFS and OS in PD‐L1 positive patients, in stage AJCC IIIC, and with 4 or more positive lymph nodes, compared with chemotherapy. Combined immunotherapy statistically improved RFS and OS in those aged < 65, with an Eastern Cooperative Oncology Group (ECOG) status of 0, and LDH ≤ ULN at baseline compared with single treatment alone. Our findings indicated that certain clinicopathological and molecular features could assist in choosing appropriate melanoma patients for immune‐based treatments.

Funder

National Natural Science Foundation of China

Natural Science Foundation of Hunan Province

Publisher

Wiley

Reference65 articles.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3